Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

Member of:

    ORCID: 0000-0003-2611-5642

    Publication year:
    All
    191 - 200 out of 236Page size: 10
    Sort by: 1st author
    1. Published

      Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

      Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

      Research output: Contribution to journal › Journal article › peer-review

    2. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

      Research output: Contribution to journal › Journal article › peer-review

    3. Published

      Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

      Deacon, Carolyn F., Nauck, M. A., Meier, J., Hücking, K. & Holst, Jens Juul, 2000, In: Journal of Clinical Endocrinology and Metabolism. 85, p. 3575-3581

      Research output: Contribution to journal › Journal article › peer-review

    4. Published

      Human colon produces fully processed glucagon-like peptide-1 (7-36 amide).

      Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: FEBS Letters. 372, p. 269-272.

      Research output: Contribution to journal › Journal article › peer-review

    5. Published

      Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo.

      Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: Journal of Clinical Endocrinology and Metabolism. 80, p. 952-957

      Research output: Contribution to journal › Journal article › peer-review

    6. Published

      Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

      Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278

      Research output: Contribution to journal › Journal article › peer-review

    7. Published

      Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.

      Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131

      Research output: Contribution to journal › Journal article › peer-review

    8. Published

      Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

      Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

      Research output: Contribution to journal › Journal article › peer-review

    9. Published

      Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

      Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

      Research output: Contribution to journal › Journal article › peer-review

    10. Published

      Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

      Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

      Research output: Contribution to journal › Journal article › peer-review

    Previous 1...16 17 18 19 20 21 22 23 24 Next

    ID: 9220